Message #74 From:
NewsBot Date: December 11, 2006 01:36:00 PM
ALNY News Alnylam Announces Public Offering of 4,700,000 Shares of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today its
intention to offer and sell approximately 4,700,000 shares of common
stock in a public offering.
The offering is underwritten by Banc of America Securities LLC. Alnylam
also intends to grant the underwriter a thirty-day option to purchase up
to approximately 705,000 additional shares.
Alnylam is a leading biopharmaceutical company developing novel
therapeutics based on RNA interference, or RNAi.
The common stock is being offered pursuant to an effective registration
statement on Form S-3 that was previously filed with the Securities and
Exchange Commission. This press release does not constitute an offer to
sell or the solicitation of an offer to buy any of the Company's common
stock, nor shall there be any sale of the common stock in any state in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state.
Copies of the preliminary prospectus supplement relating to this
offering may be obtained from Banc of America Securities LLC, Capital
Markets (Prospectus Fulfillment) by e-mail to dg.prospectus_distribution@bofasecurities.com
or by mail to Banc of America Securities LLC, Capital Markets
Operations, 100 West 33rd Street, 3rd Floor, New York, NY 10001.
Various statements in this release concerning our future expectations,
plans and prospects, including our intention to publicly offer shares of
our common stock, constitute forward-looking statements for the purposes
of the safe harbor provisions under The Private Securities Litigation
Reform Act of 1995. Actual results may differ materially from those
indicated by these forward-looking statements as a result of various
important factors, including risks related to fluctuations in our stock
price, as well as those risks more fully discussed in the “Certain
Factors That May Affect Future Results”
section of our most recent Quarterly Report on Form 10-Q on file with
the Securities and Exchange Commission. In addition, any forward-looking
statements represent our views only as of today and should not be relied
upon as representing our views as of any subsequent date. We do not
assume any obligation to update any forward-looking statements.
